a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Conditions:   Multiple Myeloma;   Plasma Cell Leukemia;   Extramedullary Plasmacytoma;   Loss of Chromosome 17p;   t(14;16);   t(4;14);   T(14;20);   1Q21 Amplification;   Complex Karyotype Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2;   Drug: Melphalan Given IV;   Drug: Fludarabine Injection;   Drug: PI and dexamethasone as maintenance therapy;   Drug: PI+IMids+Dexamethason e as Consolidated Chemotherapy Sponsor:   Institute of Hematology & Blood Diseases Hospital Recruiti...
Source: ClinicalTrials.gov - July 4, 2019 Category: Research Source Type: clinical trials